High plasma exposures of KVD900 achieved in First in Human study markedly inhibit plasma prekallikrein activation; early blockade of plasma kallikrein (PKa) may halt attacks in Hereditary Angioedema (HAE) by reducing contact system activation.

Duckworth EJ, Hampton SL, Li L, Murugesan N, Rushbrooke L, Smith M, Morten R, Maetzel A, Yea C, and Feener EP.